Telix Pharmaceuticals

TLXNasdaq Australia Health Care Biotechnology: Pharmaceutical Preparations

Market cap

$3.832 B

$11.31 -10.17%

Close of 21 Sept 2026

Revenue

—

Not reported

Earnings

—

Not reported

Shares outstanding

338,777,049

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Pharmaceutical Preparations, ranked by market cap

All 499 →

#63AbCellera BiologicsABCL$4.10B
#64Amylyx PharmaceuticalsAMLX$4.06B
#65Telix PharmaceuticalsTLX$3.83B
#66Xenon PharmaceuticalsXENE$3.78B
#67Tango TherapeuticsTNGX$3.77B

Insiders buying

All insider buying →

One open-market purchase by officers and directors of Telix Pharmaceuticals, worth $20.0K. Grants and option exercises are excluded.

Darren Charlton SmithGroup Chief Financial Officer$20.0K
2,071 shares at $9.66 on 7 Sept 2026 · filed 14 Sept 2026

What if Telix Pharmaceuticals were worth as much as…

Open the what-if tool →

Gold $30.3T

$89,362.77

Per share 7,901× higher

Bitcoin $1.72T

$5,076.51

Per share 449× higher

Nvidia $5.48T

$16,175.41

Per share 1,430× higher

Or at a round number

$5.00B $10.0B $20.0B $50.0B

Where these numbers come from

Share counts and financials for Telix Pharmaceuticals are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 22 Sept 2026. Read the methodology.